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Case study
The patient, R. A., aged 39, male, was referred to the De-
partment of Oncology at the University Hospital in Krakow 
in March 2013 due to caecal cancer with liver, peritoneal, 
and abdominal lymph nodes metastases. 
The disease was diagnosed in February 2013 when the 
patient underwent a diagnostic procedure because of ab-
dominal pain that had started approximately three months 
earlier and weight loss (approx. 10 kg in three months). 
Based on histopathological examination of samples taken 
during colonoscopy, an adenocarcinoma of the cecum was 
diagnosed. The imaging examinations revealed the pres-
ence of pathologically enlarged lymph nodes in the area of 
ileocaecal vessels and metastatic lesions in the liver (seg-
ment 4 and the boundary between segments 4 and 1). The 
patient was qualified for palliative surgery: a right-sided 
hemicolectomy was performed, with intraoperative biopsy 
of the hepatic lesions; the presence of metastases in the 
vesicorectal space was also confirmed. The postoperative 
histological examination revealed poorly differentiated 
adenocarcinoma (G3), the stage being determined as IVB 
(pT3N2bM1b). The patient was referred to the Department 
of Oncology at the University Hospital for further treat-
ment. The patient did not report any pain, and his perfor-
mance status was described as good (ECOG 0). Of note 
was chronic hepatitis B and well-controlled primary hyper-
tension in his medical history. Due to the advanced stage 
of the disease, the patient was qualified for palliative che-
motherapy according to the FOLFIRI regimen (5-fluoroura-
cil, leucovorin, irinotecan).
A systemic treatment was started, which was well toler-
ated by the patient. The treatment was continued until the 
sixth series, with control imaging examinations performed 
after the last one. Computed tomography of the abdomen 
revealed hepatomegaly and progression of metastatic le-
sions in the liver, the peritoneum, and the lymph nodes 
around the celiac trunk and the ileocecal vessels. A de-
cision was made to launch a second-line chemotherapy 
regimen, FOLFOX4 (5-fluorouracil, leucovorin, oxaliplatin) 
+ bevacizumab. The patient tolerated the treatment well; 
however, in the course of treatment, they reported an in-
cidence of dull, diffuse, poorly localised pain of a gripping 
and cramp-like nature. According to the self-assessment 
of the patient, the pain intensity on the NRS scale reached 
the level of 3/10. Meloxicam, a non-opioid analgesic of the 
NSAID group, was started at the dose of 7.5 mg per day 
combined with drotaverine. Relief of pain was achieved. 
Computed tomography performed after the 6th cycle of the 
treatment revealed a stable disease according to RECIST 
1.1 criteria. A decision was made to continue the treat-
ment using the same regimen. During the second day of 
the 7th cycle, the patient experienced strong dull pain in 
the hypogastrium, projecting at the location of the tumour 
infiltrating the pelvic organs (NRS 7–8/10), diffuse in the 
mesogastrium and the epigastrium, with girdle pain at 
the projection point for the enlarged liver and the lymph 
nodes. Due to the lack of pain control and the intensity 
of the pain the decision was made, on an emergency ba-
sis, to administer intravenous morphine. Stabilisation of 
symptoms was achieved after titrating the dose of adju-
vant medication, due to the neuropathic component of 
pain (intravenous valproate 400 mg, mianserin 10 mg PO, 
drotaverine 40 mg IV) and the start of the prophylactic 
anti-constipation regimen. The dose of morphine adminis-
tered intravenously with an infusion pump was 20 mg per 
24 hours. In the following days the route of the morphine 
administration was changed to subcutaneous, at the dose 
of 30 mg/24 hours in divided doses administered every 
4 hours, which, converted into the form of an oral dose, 
was equal to a dose of 60 mg per day, administered in 
two divided doses. In addition, a short-acting formulation 
of morphine sulphate was recommended in the event of 
breakthrough pain (BTP). Eight days after the discharge, 
the patient came to the Oncology Outpatient Clinic be-
cause of exacerbation of pain, with a similar nature and 
location in the abdomen area. After clarifying the medical 
history, the patient was found to suffer from an “end of 
dose pain”. During the outpatient visit, the dose of con-
trolled release morphine was modified by increasing the 
daily dose by approx. 50% (compared to the previously 
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prescribed dose of morphine administered orally) to 90 mg 
in three divided doses (a controlled release tablet, 30 mg 
every 8 hours). After completing check-ups, including liv-
er parameters (metastatic lesions in the liver, history of 
chronic hepatitis B) the treatment was supplemented with 
a daily dose of paracetamol – 2 g. The patient remained 
in constant contact with his doctor. During a two-week 
period, as reported by the patient, the pain control was 
satisfactory. After this period, the patient reported at the 
time of the planned 8th cycle chemotherapy; the patient 
did not complain about pain at the time of admission. On 
the third day of hospitalisation, he reported worsening of 
pain control in the hypogastrium, mesogastrium, and epi-
gastrium, with pain of girdle nature (NRS 7–8/10), and par-
oxysmal pain with persistent urinary urgency after voiding 
(NRS 7/10), with accompanying burning at the projection 
point of the bladder and incomplete emptying of the blad-
der. The patient was consulted with a palliative care spe-
cialist. While analysing the case of the patient, the nature 
of the pain (nociceptive pain in a visceral location, with 
neuropathic component), the intensity of the pain, and the 
pharmacokinetic-pharmacodynamic profile of analgesics, 
it was found that it would be beneficial to switch the opi-
oids and replace morphine with oxycodone. Intravenous 
oxycodone was administered with an infusion pump in 
the dose of 1.2 mg/hour (the initial dose was reduced by 
approx. 30% compared to the previously prescribed daily 
dose of morphine in the infusion pump).
Eventually, 1.7 mg/h of oxycodone was titrated with an 
infusion pump. Given the scheduled discharge and contin-
uation of treatment at home, the route of opioid admin-
istration was changed from intravenous to oral, with the 
daily dose of 120 mg per day administered in two divided 
doses.
Due to lack of sufficient neuropathic pain control (burn-
ing at the projection point of the bladder NRS 3/10), the 
treatment was supplemented with pregabalin (initial dose 
of 75 mg/day, gradually increased to 150 mg/day). Satis-
factory pain control was achieved, which made it possible 
to continue the systemic therapy. During subsequent visits 
by the patient to the Department of Oncology within the 
next eight weeks, the daily dose was gradually increased 
to 200 mg of controlled release oxycodone, due to wors-
ening pain control. A non-opioid analgesic (paracetamol, 
2 g/day) and pregabalin (150 mg/day) were continued, 
as well as a prophylactic anti-constipation regimen using 
an osmotically active drug (lactulose). Additionally, it was 
recommended to use a short-acting formulation of oxy-
codone hydrochloride in oral solution, in case of break-
through pain, in the dose of 30 mg (1 mg/ml), which is 
equal to 1/6th of the primary dose.
It must be emphasised that the patient, despite the 
administration of such large doses of oxycodone, had no 
impairment of consciousness, and no adverse reactions 
were observed of a nature that might be expected from 
the strong opioids. 
Re-aggravation of pain occurred two days before the 
administration of chemotherapy cycle 11. On admission to 
the Department of Oncology, the patient reported end of 
dose pain (nociceptive pain in a visceral location) with in-
tensity equal to NRS 4–5/10. The analgesia was modified, 
with an increase of the daily dose in controlled release tab-
lets to 300 mg (a dose of 100 mg every 8 hours). There was 
no deterioration of consciousness. The patient was also 
given a preparation of transmucosal fentanyl, with buccal 
administration in a titrated dose of 100 µg in case of BTP. 
The treatment with pregabalin, non-opioid analgesic, and 
prophylactic anti-constipation regimen was continued. 
A very good analgesic effect was achieved and the patient 
did not require any modification of the analgesic treat-
ment in the course of further systemic therapy. 
Chemotherapy was continued until the 7th cycle; the im-
aging studies performed after completion of the system-
ic treatment revealed disease progression, and cachexia 
was observed, with the deterioration of general condition, 
which was reflected in the results of laboratory tests (hy-
poalbuminaemia, increased activity of the lactate dehy-
drogenase, increased concentration of the carcinoembry-
onic antigen). The patient was disqualified from further 
systemic therapy and referred for treatment within a hos-
pice at home. 
Discussion
Visceral pain is a significant problem in the practice of 
clinicians dealing with cancer patients, with the pain of 
this nature found in approx. 30% of patients. It is most 
often associated with advanced malignancy, such as pan-
creatic carcinoma, gastric carcinoma, and colorectal carci-
noma and the presence of metastases in the liver, retro-
peritoneal lymph nodes, peritoneum, and mesentery. The 
symptoms may result from the presence of the tumour, as 
well as the ensuing sub- or obstruction. Reported symp-
toms most often include poorly localised pain of a burning, 
gripping, and cramp-like nature. It is also often accompa-
nied by autonomic symptoms, such as nausea, vomiting, 
and increased sweating. Currently, treatment guidelines 
do not identify visceral pain as requiring different thera-
peutic approaches, and the recommended procedure is 
no different from that for somatic pain. Clinical practice 
shows, however, that knowledge of the pathogenesis of 
visceral pain and the differences in the pharmacodynam-
ics and pharmacokinetics of available analgesic drugs 
make it possible to optimise the treatment of visceral pain. 
In the treatment of visceral pain, due to the location of the 
opioid receptors, the preferred drugs are opioid receptor 
agonists of mixed µ and κ type. 
Oxycodone is a semi-synthetic derivative of thebaine. 
The main mechanism of action of oxycodone is associated 
with stimulation of the peripheral and central opioid re-
ceptors of the µ and κ type. It is thought that κ receptors 
constitute an essential part in the analgesic mechanism 
of action of oxycodone [1]. Opioid receptors of the κ type 
are involved in the mechanisms of visceral pain formation, 
and hence the drug has high therapeutic efficacy, partic-
ularly in visceral location of pain [1]. By interacting with 
the G-protein, oxycodone causes the potassium channels 
to open and blocks activation of voltage-dependent calci-
um channels. The consequence of the described effects is 
a reduction of the excitability of nerve cells. Although oxy-
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codone - compared with morphine – has lower intrinsic ac-
tivity in relation to the µ-type receptor, its analgesic effect 
is stronger [1–4]. This is due to the fact that, at comparable 
concentrations in the blood of both opioid analgesics, the 
concentration of unbound oxycodone in the brain is six-
fold higher compared with morphine. In the treatment of 
cancer pain, oxycodone is characterised by optimal phar-
macokinetic profile and a high safety profile in patients 
concomitantly treated with other drugs. The interactions 
due to inhibition of CYP3A4 and CYP2D6 activity by other 
drugs have virtually no clinical significance [1, 5, 6]. Clini-
cally significant interactions may be associated with con-
comitant administration of drugs: depressants of central 
nervous system functions and anticholinergic drugs. 
Oxycodone, administered orally, is about twice as 
strong as morphine, is administered parenterally, and is 
only slightly stronger; the coefficient of equivalent doses of 
intravenous morphine relative to oxycodone is on the level 
of 1:0.7. In clinical practice, however, it has been observed 
that in patients with visceral pain locations, similar paren-
teral doses of oxycodone and morphine are often needed. 
It is worth mentioning that the most effective method to 
determine adequate oxycodone doses in relation to the 
present pain is titrating the dose. If the patient experi-
ences pain of high intensity and has not been previously 
treated with a strong opioid, titration starts with an intra-
venous bolus. It is advisable, depending on the intensity 
of pain, to perform slow administration of 1-2 mg of oxy-
codone every 5 minutes [1]. If, for example, the oxycodone 
dose needed to achieve effective analgesia is titrated at 8 
mg, the patient should receive a continuous intravenous 
infusion of oxycodone in the dose of 1 mg/hour (half-life 
equal to approx. 4 hours means that in that time a half of 
the dose, or 4 mg, must be administered to maintain con-
stant therapeutic concentration of the drug). In the case of 
an alternative use of subcutaneous, the initial daily dose 
of oxycodone should be equal to 7.5 mg [6]. Oxycodone is 
available as an oral formulation (OxyNorm® oral solution 
– as a fast-acting preparation and controlled-release tab-
lets OxyContin™ with the AcroContin™ system providing 
biphasic release of the drug) and in a form intended for 
parenteral administration (OxyNorm® ampoules). What is 
also important is the fact that an innovative oral formula-
tion is available on the pharmaceutical market, which is 
a combination of oxycodone with naloxone (Targin®) [1, 2, 
7], recommended for patients with pain and constipation 
after treatment with opioids.
The literature contains few works on the use of high 
doses of oxycodone in the treatment of cancer pain. In 
2011, Mercadante et al. published the results of an analysis 
of 212 patients who used controlled-release oxycodone as 
the primary analgesic [8]. Patients were assigned to one of 
three groups: in the first group, 129 patients were treated 
with the daily dose of less than 120 mg; in the next group, 
43 patients received higher daily doses of 120–240 mg; 
and in the last group, 40 patients received the drug in the 
dose of 240 mg/day. The mean daily dose of oral oxyco-
done was 141 ±167 mg (dose range 10–960 mg), and in the 
individual groups it was equal to 48.4 ±25 mg, 156.5 ±30.5 
mg, and 435 ±196 mg, respectively. In this study, there was 
no difference in terms of gender, primary diagnosis, and 
the mechanism of pain. Adverse reactions were mild and 
were not associated with the administered dose of oxyco-
done. The authors concluded that at high doses, the oxy-
codone drug is safe and effective [8, 9]. 
In conclusion, oxycodone is a valuable alternative in 
the treatment of pain in cancer patients. Compared to 
morphine, oxycodone has a different receptor profile, in-
cluding the impact on kappa opioid receptors, which may 
be of particular significance in the treatment of neuro-
pathic and visceral pain. Other features that characterise 
oxycodone include high bioavailability, metabolism to 
inactive metabolites, little risk of interaction with other 
concomitantly used drugs, optimum safety profile com-
pared to other opioids, and minimal immunosuppressive 
activity [10, 11].
Collaboration with Mundipharma Polska. 
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